Retatrutide
Triple incretin receptor agonist
An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.
Mazdutide
Also cited in the literature as IBI362 / LY3305677
An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.
Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.
Hormone & signalling research
Research stage: Phase 3 results reported in Chinese study groups
Cells
Animal studies
Human trials
The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.
What it is
Mazdutide is a laboratory-made version of oxyntomodulin, a hormone produced in the gut. It acts on GLP-1 and glucagon receptors.
Published studies also called it IBI362 or LY3305677.
How researchers think it works
Studies found that mazdutide activated both GLP-1 and glucagon receptors. Researchers linked these targets with blood sugar control and the way the body used energy.
Researchers designed the peptide around oxyntomodulin because that natural hormone also acts on both receptors.
What has research seen in people?
Trials, mostly run in China, reported reductions in body weight and improvements in blood sugar measures compared with placebo in adults with obesity or type 2 diabetes.
Stomach and bowel effects were again the most commonly reported problem.
Because nearly all participants were recruited in one country, researchers said it was unclear how far the findings carry across to other populations.
Where this material is listed
For laboratory research use only. Not a medicine and not for human or animal use.
Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.
What studies have found
- Phase 2 trials published in The Lancet Diabetes & Endocrinology and other journals studied adults with overweight, obesity or type 2 diabetes. Researchers reported changes in body weight and blood sugar compared with placebo.
- Researchers also reported phase 3 results from trials in China. Published records described a regulatory review there.
- Digestive problems were the most commonly reported side effects.
What we still do not know
- Most participants were enrolled in China. Researchers said that more studies were needed to know whether the findings applied to other populations.
- Little long-term evidence was available at the time of writing.
Sources
Related profiles
BPC-157
Synthetic pentadecapeptide
A laboratory-made peptide made of 15 amino acids. Almost all published research involved cells or rodents rather than people.
TB-500
Peptide fragment of thymosin beta-4
A laboratory-made piece of thymosin beta-4, a natural protein. Researchers mainly examined it in early cell and animal studies.